Tradestie Institutional Equity Comparison Engine
ANL vs TYRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANL Overall Edge
ANL Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ANL (ANL) driven by superior Momentum & Technical, Options & Structure while TYRA counters with relative strength in Growth & Margin. Fundamentally, ANL trades at N/M Forward P/E with -123.5% operating margin (+178.1% YoY revenue) versus TYRA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ANL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against TYRA sits in BREAKDOWN (3rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ANL N/M vs TYRA N/M Fwd P/E
Growth & Margin Winner
TYRA
Op Margin -123.5% vs 0.0% ยท YoY +178.1% vs +0.0%
Momentum & Technical Winner
ANL
1Y +560.3% vs +26.8% ยท 52W Pos 56% vs 20%
Options & Structure Winner
ANL
UNCLASSIFIED (N/A IV) vs BREAKDOWN (3rd %ile IV)
ANL
US Equity
ANL
Institutional Equity
$9.97
-6.03% 1D
Market Cap
$677.5M
1M Return
-9.61%
1Y Return
+560.26%
Forward P/E
N/M
Unified AI Score
48.3 / 100
HOLD
Tech 48.0
Fund 52.0
Flow 50.0
Mom 50.0
TYRA
NASDAQ
Tyra Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$19.77
-1.27% 1D
Market Cap
$1.3B
1M Return
+6.75%
1Y Return
+26.81%
Forward P/E
N/M
Unified AI Score
33.0 / 100
SELL
Tech 25.0
Fund 46.0
Flow 69.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ANL +560.26%
TYRA +26.81%
Spread: +533.45 pp (ANL Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ANL TTM Op. Margin: -123.5%
TYRA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANL vs TYRA. Trailing 12-month operating profitability (ANL -123.5% vs TYRA 0.0%) and valuation multiples (ANL N/M vs TYRA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANL | TYRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $677.5M | $1.3B | Larger Scale | TYRA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +178.1% | +0.0% | Higher Growth | ANL |
| Operating Margin (TTM) Profitability | -123.5% | 0.0% | Higher Margin | TYRA |
| Net Profit Margin Profitability | -124.8% | 0.0% | Higher Margin | TYRA |
| Return on Equity (ROE) Capital Efficiency | -20.2% | -34.9% | Higher ROE | ANL |
| 52-Week Range Position Momentum | 56% ($1โ$17) | 20% ($15โ$41) | Stronger Trend | ANL |
| Beta / 30D Volatility Risk Regime | 2.61ฮฒ ยท 79% Vol | 0.79ฮฒ ยท 49% Vol | Lower Realized Risk | TYRA |
| Unified Institutional Score Composite Signal | 48.3 / 100 (HOLD) | 33.0 / 100 (SELL) | Higher Composite | ANL |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ANL vs TYRA Buy Guide
ANL
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
TYRA
BREAKDOWN
76d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
3rd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ANL nor TYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.